Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel anti-virulence gene revealed by proteomic analysis in Shigella flexneri 2a.

Proteome science·2010
Same author

Delivery of siRNA therapeutics: barriers and carriers.

The AAPS journal·2010
Same author

Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial.

Chinese journal of integrative medicine·2010
Same author

Prognostic factors and outcome of 438 Chinese patients with hepatocellular carcinoma underwent partial hepatectomy in a single center.

World journal of surgery·2010
Same author

Proteomic analysis of hydrogen photoproduction in sulfur-deprived Chlamydomonas cells.

Journal of proteome research·2010
Same author

MSU-S mesoporous materials: an efficient catalyst for isomerization of alpha-pinene.

Bioresource technology·2010

Related Experiment Video

Updated: Jan 6, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup

Shun Lu1, Jie Wang2, Yan Yu3

  • 1Department of Oncology, School of Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Xuhui District, 241 Huaihai West Road, Shanghai, 200020, China. shun_lu@hotmail.com.

Oncology and Therapy
|September 14, 2025
PubMed
Summary

First-line tislelizumab plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) in advanced non-squamous non-small cell lung cancer (nsq-NSCLC) patients with high PD-L1 expression (≥50%). Efficacy was consistent across PD-L1 subgroups.

Keywords:
Anti-PD-1 antibodyFirst lineNon-small cell lung cancerStage IIIB-IVTislelizumab

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

Related Experiment Videos

Last Updated: Jan 6, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trials

Background:

  • The RATIONALE-304 trial investigated first-line tislelizumab plus chemotherapy versus chemotherapy in advanced non-squamous non-small cell lung cancer (nsq-NSCLC).
  • This analysis specifically examined outcomes in patients with tumor cell programmed death-ligand 1 (PD-L1) expression ≥50%.

Purpose of the Study:

  • To evaluate the efficacy and safety of first-line tislelizumab plus chemotherapy in advanced nsq-NSCLC patients with high PD-L1 expression (≥50%).
  • To assess progression-free survival (PFS) and overall survival (OS) in this patient subgroup.

Main Methods:

  • Patients with stage IIIB/IV nsq-NSCLC were randomized to receive tislelizumab plus chemotherapy and pemetrexed, or chemotherapy and pemetrexed.
  • The primary endpoint was independent review committee (IRC)-assessed PFS; secondary endpoints included OS, objective response rates, and safety.

Main Results:

  • In the PD-L1 ≥50% population (n=110), median PFS was 17.2 months with tislelizumab plus chemotherapy versus 4.6 months with chemotherapy alone (HR 0.29).
  • Median OS was 41.9 months versus 13.1 months, respectively (HR 0.38).
  • Efficacy was consistent across PD-L1 expression subgroups (50-89% and ≥90%), and the safety profile was manageable.

Conclusions:

  • First-line tislelizumab plus chemotherapy offers a clinically meaningful improvement in PFS and OS for advanced nsq-NSCLC patients with PD-L1 expression ≥50%.
  • The treatment demonstrated consistent efficacy across high PD-L1 expression levels.